BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: IMPROVEMENTS IN PSARC OVER 24 WEEKS IN THE PHASE 3 BE OPTIMAL TRIAL

被引：0
|
作者：
McInnes, Iain [1 ]
Ink, Barbara [2 ]
Bajracharya, Rajan [2 ]
Taieb, Vanessa [3 ]
Tillett, William R. [4 ]
机构：
[1] Univ Glasgow, IBM Coll Med Vet & Life Sci, Glasgow, Scotland
[2] UCB Pharma, Rheumatol, Slough, England
[3] UCB Pharma, Rheumatol, Colombes, France
[4] Univ Bath, Royal Natl Hosp Rheumat Dis, Dept Life Sci, Bath, England
来源：
RHEUMATOLOGY | 2023年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P171
引用
收藏
页数：2
相关论文
共 50 条
  • [1] BIMEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO TNF INHIBITORS: IMPROVEMENTS OF PSARC OVER 16 WEEKS IN THE PHASE 3 BE COMPLETE TRIAL
    Sharma, Poonam
    Jadon, Deepak R.
    McGonagle, Dennis
    Ink, Barbara
    Assudani, Deepak
    Taieb, Vanessa
    Coates, Laura C.
    RHEUMATOLOGY, 2023, 62
  • [2] BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY
    McInnes, I.
    Coates, L.
    Landewe, R. B. M.
    Mease, P. J.
    Ritchlin, C. T.
    Tanaka, Y.
    Asahina, A.
    Gossec, L.
    Gottlieb, A. B.
    Warren, R. B.
    Ink, B.
    Assudani, D.
    Coarse, J.
    Bajracharya, R.
    Merola, J. F.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 206 - 207
  • [3] Bimekizumab efficacy and safety in biologic bDMARD-naive patients with psoriatic arthritis was consistent with or without methotrexate: 52-week results from the phase 3 active reference study BE OPTIMAL
    McInnes, I.
    Mease, P.
    Tanaka, Y.
    Behrens, F.
    Gossec, L.
    Husni, M.
    Kristensen, L.
    Warren, R.
    Ink, B.
    Bajracharya, R.
    Coarse, J.
    Eells, J.
    Gottlieb, A.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 : 78 - 81
  • [4] Bimekizumab in bDMARD-naive patients with psoriatic arthritis and skin involvement: Analysis of radiographic progression at Week 16 of BE OPTIMAL, a phase 3, multicenter, randomized, placebo- controlled, active reference study
    Merola, Joseph F.
    Asahina, Akihiko
    Gisondi, Paolo
    Thaci, Diamant
    Gladman, Dafna D.
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Coarse, Jason
    Landewe, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB128 - AB128
  • [5] Bimekizumab in bDMARD-naive patients with psoriatic arthritis and skin involvement: Analysis of radiographic progression at Week 16 of BE OPTIMAL, a phase 3, multicenter, randomized, placebo-controlled, active reference study
    Merola, Joseph F.
    Asahina, Akihiko
    Gisondi, Paolo
    Thaci, Diamant
    Gladman, Dafna D.
    Ink, Barbara
    Assudani, Deepak
    Bajiracharya, Rajan
    Coarse, Jason
    Landewe, Robert
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 97 - 97
  • [6] Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naive patients with active psoriatic arthritis (SPIRIT-P1)
    Gottlieb, Alice B.
    Strand, Vibeke
    Kishimoto, Mitsumasa
    Mease, Philip
    Thaci, Diamant
    Birt, Julie
    Lee, Chin H.
    Shuler, Catherine L.
    Lin, Chen-Yen
    Gladman, Dafna D.
    RHEUMATOLOGY, 2018, 57 (10) : 1777 - 1788
  • [7] Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo- controlled, phase 3 trial (BE OPTIMAL)
    McInnes, Iain B.
    Asahina, Akihiko
    Coates, Laura C.
    Landewe, Robert
    Merola, Joseph F.
    Ritchlin, Christopher
    Tanaka, Yoshiya
    Gossec, Laure
    Gottlieb, Alice B.
    Warren, Richard B.
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Shende, Vishvesh
    Coarse, Jason
    Mease, Philip J.
    LANCET, 2023, 401 (10370): : 25 - 37
  • [8] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 104 WEEKS RESULTS FROM A PHASE 3 TRIAL
    McInnes, Iain B.
    Mease, Philip
    Ritchlin, Christopher T.
    Rahman, Proton
    Gottlieb, Alice B.
    Kirkham, Bruce
    RHEUMATOLOGY, 2017, 56 : 76 - 76
  • [9] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 104 Weeks Results from a Phase 3 Trial
    McInnes, Kin B.
    Mease, Philip J.
    Ritchlin, Christopher T.
    Rahman, Proton
    Gottlieb, Alice B.
    Kirkham, Bruce
    Kajekar, Radhika
    Delicha, Evie Maria
    Pricop, Luminita
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [10] Ixekizumab provides improvements through 52 weeks in physical function, quality of life, and work productivity in biologic diseasemodifying antirheumatic drug (bDMARD) naive patients with active psoriatic arthritis (PsA)
    Gottlieb, A. B.
    Husni, M. E.
    Shuler, C. L.
    Burge, R.
    Lin, C. -Y.
    Lee, C. H.
    Gladman, D. D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 4 - 4
12345